Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vinblastine + methotrexate + fluorouracil
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of vinblastine (a vinca alkaloid that inhibits microtubule polymerization), methotrexate (an antimetabolite that inhibits dihydrofolate reductase), and fluorouracil (a pyrimidine analog that interferes with DNA synthesis). This combination is not commonly documented in standard treatment protocols compared to similar combinations like VMF (vinorelbine + methotrexate + fluorouracil) which is used in metastatic breast cancer.
02
Targets
TUBB (Tubulin (alpha and beta subunits))DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on vinblastine + methotrexate + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vinblastine + methotrexate + fluorouracil.